News
Ortikos Now Available for Mild to Moderate Crohn Disease
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Your search for oral corticosteroids returned 190 results
News
Breztri Aerosphere Approved as Triple-Combination Therapy Inhaler for COPD
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
News
Oral Corticosteroid Bursts Carry Risk for Severe Adverse Events
Highest rates of adverse events seen within first month after initiating short course of oral steroids.
News
Dupixent Prefilled Pen Approval Provides Additional Administration Option
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
News
Guideline Details Pharmacologic Management of COPD
Clinical practice guideline addresses 6 emerging questions around COPD management.
Drugs in the Pipeline
Voclosporin NDA for Lupus Nephritis Submitted to FDA
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
News
Dupixent Approval Expanded to Pediatric Patients With Atopic Dermatitis
The FDA has expanded the approval of Dupixent® (dupilumab; Regeneron and Sanofi) to include patients aged 6 to 11 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
chart
Chemotherapy-Induced Nausea and Vomiting Guidelines: Prophylaxis
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
ATS 2020
Masitinib Significantly Reduced Exacerbations in Uncontrolled Severe Asthma
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
ATS 2020
COPD Maintenance Therapy: Adverse Outcomes With Tiotropium/Olodaterol vs LABA/ICS
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
